Bilateral Atypical Femoral Fracture in a Bisphosphonate-Naïve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review
- PMID: 38792327
- PMCID: PMC11122202
- DOI: 10.3390/jcm13102785
Bilateral Atypical Femoral Fracture in a Bisphosphonate-Naïve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review
Abstract
The benefits of denosumab as an antiresorptive therapy and in reducing fragility fractures are well documented. However, its association with atypical femur fractures (AFFs), especially in the absence of prior bisphosphonate use, remains poorly understood and warrants further investigation. This case report presents a rare instance of bilateral AFFs in a 78-year-old bisphosphonate-naïve patient with a history of long-term denosumab therapy for previous metastatic breast cancer. Management involved intramedullary nail fixation after initial presentation with a unilateral AFF and a recommendation to cease denosumab therapy. However, the patient subsequently experienced a contralateral periprosthetic AFF below a total hip implant 5 months thereafter and was treated with open reduction internal fixation. This case report highlights the critical need for orthopedic surgeons to maintain a high level of suspicion and vigilance in screening for impending AFFs, especially in patients with a prolonged history of denosumab therapy without prior bisphosphonate use. Furthermore, the growing report of such cases emphasizes the urgent need for comprehensive research aimed at refining treatment protocols that balance the therapeutic benefits of denosumab and its associated risks of AFFs.
Keywords: atypical femoral fracture; bisphosphonate; bone antiresorptive therapy; denosumab; subtrochanteric fracture.
Conflict of interest statement
The authors declare no direct conflicts of interest in connection with the submitted article. However, interests that may be perceived as influencing the representation or interpretation of the reported research results are reported by authors.: I.S.H.: Foundation for Orthopedic Trauma: Research support; Irrimax Corporation: Research support; LifeNet Health: Paid consultant. F.A.L.: AAOS: Board or committee member; AO: Unpaid consultant; Biomet: IP royalties, Paid consultant, Paid presenter or speaker, Research support; DePuy, A Johnson & Johnson Company: IP royalties, Research support; Orthopedic Trauma Association: Board or committee member; Stryker: IP royalties; Synthes: Paid consultant; Paid presenter or speaker. R.S.Y.: American Association of Hip and Knee Surgeons: Board or committee member; AO Foundation: Research support; AO Innovation Translation Center: Research support; Arthrex, Inc: IP royalties, Paid consultant; Bicomposites: Research support; Biomet: Research support; COTA: Research support; DePuy, A Johnson & Johnson Company: Paid consultant, Research support; Foundation for Physician Advancement: Board or committee member; Foundation for Orthopedic Trauma: Board or committee member; Irrimax: Research support; MiCare Health: Paid consultant; OMEGA: Research support; Organogenesis: Research support; ORintelligence: Stock or stock Options; OrthoGrid: Paid consultant; Orthopedic Trauma Association: Board or committee member, ORTHOXEL: Paid consultant, Pacira: Research support; SI-Bone: Paid consultant, Research support; Springer: Publishing royalties, financial or material support; Stryker: IP royalties; Paid consultant; Synthes: Paid consultant; Research support, Use-Lab: Paid consultant; WNT Scientific: Stock or stock Options.
Figures






Similar articles
-
Peri-implant atypical femoral fracture after nail or plate osteosynthesis.J Orthop Sci. 2022 Jul;27(4):866-875. doi: 10.1016/j.jos.2021.04.008. Epub 2021 May 27. J Orthop Sci. 2022. PMID: 34052080
-
Atypical femoral fracture in a bisphosphonate-naïve patient on denosumab for osteoporosis.Arch Osteoporos. 2022 Oct 1;17(1):131. doi: 10.1007/s11657-022-01166-x. Arch Osteoporos. 2022. PMID: 36180610
-
Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report.Calcif Tissue Int. 2022 Jul;111(1):96-101. doi: 10.1007/s00223-022-00952-6. Epub 2022 Feb 8. Calcif Tissue Int. 2022. PMID: 35132455
-
Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.Osteoporos Int. 2016 Feb;27(2):827-32. doi: 10.1007/s00198-015-3355-z. Osteoporos Int. 2016. PMID: 26501556 Review.
-
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2014 Jan;29(1):1-23. doi: 10.1002/jbmr.1998. Epub 2013 Oct 1. J Bone Miner Res. 2014. PMID: 23712442 Review.
Cited by
-
Bisphosphonate beak without the bisphosphonate: atypical femoral fracture with denosumab.BMJ Case Rep. 2025 Jun 12;18(6):e265400. doi: 10.1136/bcr-2025-265400. BMJ Case Rep. 2025. PMID: 40506101 Free PMC article.
-
The definition of atypical femoral fractures should include periprosthetic femoral fractures (PAFFs).Osteoporos Int. 2025 Mar;36(3):539-546. doi: 10.1007/s00198-025-07401-8. Epub 2025 Feb 7. Osteoporos Int. 2025. PMID: 39920401 Free PMC article.
References
-
- Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., Cosman F., Curtis J.R., Dell R., Dempster D.W., et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2014;29:1–23. doi: 10.1002/jbmr.1998. - DOI - PubMed
-
- Takahashi M., Ozaki Y., Kizawa R., Masuda J., Sakamaki K., Kinowaki K., Umezu T., Kondoh C., Tanabe Y., Tamura N., et al. Atypical Femoral Fracture in Patients with Bone Metastasis Receiving Denosumab Therapy: A Retrospective Study and Systematic Review. BMC Cancer. 2019;19:980. doi: 10.1186/s12885-019-6236-6. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources